Nano-NRTIs: Efficient Inhibitors of HIV Type-1 in Macrophages with a Reduced Mitochondrial Toxicity | Zendy

Serguei V. Vinogradov | Zendy; Larisa Y. Poluektova | Zendy; Edward Makarov | Zendy; Trevor Gerson | Zendy; Madapathage T. Senanayake | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nano-NRTIs: Efficient Inhibitors of HIV Type-1 in Macrophages with a Reduced Mitochondrial Toxicity

Author(s) -

Serguei V. Vinogradov,

Larisa Y. Poluektova,

Edward Makarov,

Trevor Gerson,

Madapathage T. Senanayake

Publication year - 2010

Publication title -

antiviral chemistry and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.919

H-Index - 51

eISSN - 2040-2066

pISSN - 0956-3202

DOI - 10.3851/imp1680

Subject(s) - nanocarriers , zalcitabine , didanosine , cytotoxicity , zidovudine , nanogel , nucleoside reverse transcriptase inhibitor , chemistry , reverse transcriptase inhibitor , stavudine , pharmacology , drug delivery , biology , biochemistry , virology , reverse transcriptase , drug , in vitro , virus , rna , organic chemistry , viral disease , gene

Macrophages serve as a depot for HIV type-1 (HIV-1) in the central nervous system. To efficiently target macrophages, we developed nanocarriers for potential brain delivery of activated nucleoside reverse transcriptase inhibitors (NRTIs) called nano-NRTIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research